Boston Medical Center
- Type
- Teaching hospital
- Where
- Boston, MA
- Medicare CCN
- 220031
- Received
- $6,773,688 in 483 records, 2025 ($924,243 general, $5,849,444 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Boston Medical Center Corporation Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Nonprofit contractor: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Patent assignee: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Trademark owner: Boston Medical Center Corporation Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 73 | $924,243 |
| 2025 | Research payment | 410 | $5,849,444 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 410 | $5,849,444 |
| Grant | 13 | $446,425 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 23 | $175,843 |
| Charitable Contribution | 9 | $167,353 |
| Education | 16 | $119,061 |
| Long term medical supply or device loan | 6 | $12,859 |
| Debt forgiveness | 4 | $1,812 |
| Space rental or facility fees (teaching hospital only) | 1 | $748 |
| Food and Beverage | 1 | $139 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | $292,646 | Research payment | In-kind items and services | GARDASIL 9 Biological, VACCINE | An Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose Vaccination Regimen over 6 months Amon | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $15,450 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $8,666 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $7,224 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2025 | |
| 2025-12-31 | Sequel Med Tech, LLC | $7,200 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Stryker Corporation | $3,477 | Long term medical supply or device loan | In-kind items and services | CORE Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $3,477 | Long term medical supply or device loan | In-kind items and services | CORE Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Sequel Med Tech, LLC | $3,200 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $3,200 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $3,200 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $3,200 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $2,584 | Education | In-kind items and services | IMAGE 1 Device, T-VIDEOIMAGING | 2025 | |
| 2025-12-31 | Sequel Med Tech, LLC | $2,223 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $2,223 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $2,223 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $2,223 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $2,223 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $2,160 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $2,034 | Education | In-kind items and services | HOPKINS Device, K-LAPAROSCOPY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $2,034 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2025 | |
| 2025-12-31 | Stryker Corporation | $1,860 | Long term medical supply or device loan | In-kind items and services | STRYKER Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $1,860 | Long term medical supply or device loan | In-kind items and services | STRYKER Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Sequel Med Tech, LLC | $960 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $960 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $960 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $960 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $877 | Education | In-kind items and services | 2025 | ||
| 2025-12-31 | KARL STORZ Endoscopy-America | $728 | Education | In-kind items and services | n.a. Device, K-LAPAROSCOPY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $728 | Education | In-kind items and services | n.a. Device, K-LAPAROSCOPY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $728 | Education | In-kind items and services | n.a. Device, K-LAPAROSCOPY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $728 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2025 | |
| 2025-12-31 | Sequel Med Tech, LLC | $666 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $666 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $666 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $666 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $666 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Stryker Corporation | $602 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $422 | Education | In-kind items and services | 2025 | ||
| 2025-12-31 | KARL STORZ Endoscopy-America | $282 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $213 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $185 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2025 | |
| 2025-12-31 | Stryker Corporation | $182 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | Merck Sharp & Dohme LLC | $175 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $154 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2025 | |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $136 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2025 | |
| 2025-12-31 | Stryker Corporation | $81 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-29 | PFIZER INC. | $50,000 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | SURVEILLANCE OF INVASIVE PNEUMOCOCCAL DISEASES IPD IN MASSACHUSETTS CHILDREN | 2025 |
| 2025-12-22 | Novo Nordisk AS | $8,445 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2025 |
| 2025-12-22 | Merck Sharp & Dohme LLC | $8,185 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2025 |
| 2025-12-22 | Janssen Research & Development, LLC | $6,723 | Research payment | Cash or cash equivalent | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatm | 2025 | |
| 2025-12-22 | Janssen Research & Development, LLC | $4,272 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car | 2025 |
| 2025-12-22 | Novo Nordisk AS | $3,098 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2025 |
| 2025-12-22 | Novo Nordisk AS | $1,500 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2025 |
| 2025-12-19 | F. Hoffmann-La Roche AG | $20,963 | Research payment | Cash or cash equivalent | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan | 2025 | |
| 2025-12-19 | F. Hoffmann-La Roche AG | $4,030 | Research payment | Cash or cash equivalent | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan | 2025 | |
| 2025-12-19 | F. Hoffmann-La Roche AG | $3,588 | Research payment | Cash or cash equivalent | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan | 2025 | |
| 2025-12-19 | F. Hoffmann-La Roche AG | $3,422 | Research payment | Cash or cash equivalent | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan | 2025 | |
| 2025-12-19 | F. Hoffmann-La Roche AG | $2,959 | Research payment | Cash or cash equivalent | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan | 2025 | |
| 2025-12-19 | F. Hoffmann-La Roche AG | $2,564 | Research payment | Cash or cash equivalent | UC P3: Double-Blind Treat Straight Through | 2025 | |
| 2025-12-19 | Madrigal Pharmaceuticals | $195 | Research payment | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET | 2025 |
| 2025-12-18 | Janssen Research & Development, LLC | $4,742 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2025 | |
| 2025-12-18 | Organon Llc | $14 | Long term medical supply or device loan | In-kind items and services | JADA SYSTEM Device, POSTPARTUM UTERINE HEMORRHAGING | 2025 | |
| 2025-12-17 | Medtronic, Inc. | $20,880 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-15 | Janssen Research & Development, LLC | $5,434 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced | 2025 | |
| 2025-12-12 | Davol Inc. | $20,930 | Research payment | Cash or cash equivalent | DVL-HE-018 | 2025 | |
| 2025-12-12 | SANOFI PASTEUR INC. | $7,500 | Research payment | Cash or cash equivalent | Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, I | 2025 | |
| 2025-12-10 | Takeda Pharmaceuticals U.S.A., Inc. | $292 | Research payment | Cash or cash equivalent | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSI | 2025 | |
| 2025-12-05 | Janssen Research & Development, LLC | $43,692 | Research payment | Cash or cash equivalent | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatm | 2025 | |
| 2025-12-04 | E.R. Squibb & Sons, L.L.C. | $39,978 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS | 2025 | |
| 2025-12-04 | Janssen Research & Development, LLC | $8,515 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced | 2025 | |
| 2025-12-04 | Madrigal Pharmaceuticals | $5,423 | Research payment | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET | 2025 |
| 2025-12-04 | ABBVIE INC. | $2,437 | Research payment | Cash or cash equivalent | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Ch | 2025 | |
| 2025-12-02 | Gilead Sciences, Inc. | $28,028 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-01 | Humacyte Global, Inc. | $9,664 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-12-01 | Humacyte Global, Inc. | $2,491 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-11-30 | Sequel Med Tech, LLC | $3,200 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-11-30 | Sequel Med Tech, LLC | $2,223 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-11-30 | Sequel Med Tech, LLC | $2,223 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-11-30 | Sequel Med Tech, LLC | $2,223 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-11-30 | Sequel Med Tech, LLC | $960 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-11-30 | Sequel Med Tech, LLC | $666 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-11-30 | Sequel Med Tech, LLC | $666 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-11-30 | Sequel Med Tech, LLC | $666 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-11-30 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-11-30 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-11-30 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-11-30 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-11-30 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-11-30 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-11-28 | Janssen Research & Development, LLC | $23,400 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (AQUARIUS) | 2025 |
| 2025-11-28 | Janssen Research & Development, LLC | $2,460 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (AQUARIUS) | 2025 |
| 2025-11-28 | Janssen Research & Development, LLC | $1,950 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (AQUARIUS) | 2025 |
| 2025-11-26 | Eidos Therapeutics, Inc. | $19,225 | Research payment | Cash or cash equivalent | Attruby Drug, Cardiomyopathy | A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis P | 2025 |
| 2025-11-26 | Eidos Therapeutics, Inc. | $3,900 | Research payment | Cash or cash equivalent | Attruby Drug, Cardiomyopathy | A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis P | 2025 |
| 2025-11-25 | Genentech, Inc. | $7,418 | Research payment | Cash or cash equivalent | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan | 2025 | |
| 2025-11-25 | Genentech, Inc. | $3,055 | Research payment | Cash or cash equivalent | UC P3: Double-Blind Treat Straight Through | 2025 | |
| 2025-11-25 | Genentech, Inc. | $3,042 | Research payment | Cash or cash equivalent | UC P3: Double-Blind Treat Straight Through | 2025 | |
| 2025-11-25 | Madrigal Pharmaceuticals | $1,903 | Research payment | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET | 2025 |
| 2025-11-25 | Madrigal Pharmaceuticals | $195 | Research payment | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET | 2025 |
| 2025-11-21 | Janssen Research & Development, LLC | $5,027 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2025 | |
| 2025-11-18 | Gilead Sciences, Inc. | $6,605 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-11-17 | Merck Sharp & Dohme LLC | $28,320 | Research payment | In-kind items and services | GARDASIL 9 Biological, VACCINE | An Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose Vaccination Regimen over 6 months Amon | 2025 |
| 2025-11-17 | Genentech, Inc. | $2,730 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | 2025 |
| 2025-11-14 | Genentech, Inc. | $928 | Research payment | Cash or cash equivalent | Tecentriq Biological, BioOncology | Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC | 2025 |
| 2025-11-12 | Takeda Pharmaceuticals U.S.A., Inc. | $10,648 | Research payment | Cash or cash equivalent | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSI | 2025 | |
| 2025-11-10 | Abbott Laboratories | $460 | Research payment | Cash or cash equivalent | ESPRIT Device, Vascular | NCT04227899--LIFE-BTK Randomized Controlled Trial | 2025 |
| 2025-11-07 | Genentech, Inc. | $18,142 | Research payment | Cash or cash equivalent | UC P3: Double-Blind Treat Straight Through | 2025 | |
| 2025-11-07 | Janssen Research & Development, LLC | $8,112 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car | 2025 |
| 2025-11-07 | Genentech, Inc. | $4,225 | Research payment | Cash or cash equivalent | UC P3: Double-Blind Treat Straight Through | 2025 | |
| 2025-11-07 | Genentech, Inc. | $1,950 | Research payment | Cash or cash equivalent | UC P3: Double-Blind Treat Straight Through | 2025 | |
| 2025-11-07 | Madrigal Pharmaceuticals | $1,903 | Research payment | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET | 2025 |
| 2025-11-06 | PFIZER INC. | $96 | Research payment | In-kind items and services | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2025 |
| 2025-11-06 | PFIZER INC. | $96 | Research payment | In-kind items and services | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2025 |
| 2025-11-05 | Theratechnologies Inc. | $153,725 | Research payment | Cash or cash equivalent | TROGARZO Drug, HIV | A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab | 2025 |
| 2025-11-05 | Theratechnologies Inc. | $35,035 | Research payment | Cash or cash equivalent | TROGARZO Drug, HIV | A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab | 2025 |
| 2025-11-05 | Indivior Inc. | $19,998 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2025 | |
| 2025-11-05 | ABBVIE INC. | $6,910 | Research payment | Cash or cash equivalent | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Ch | 2025 | |
| 2025-11-05 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2025 | |
| 2025-11-05 | KLS-Martin L.P. | $3,750 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-11-05 | Takeda Pharmaceuticals U.S.A., Inc. | $195 | Research payment | Cash or cash equivalent | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSI | 2025 | |
| 2025-11-04 | Abbott Laboratories | $1,199 | Research payment | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | ISM2309001A--Janus 1 | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $3,200 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $3,200 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $3,200 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $3,200 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $3,200 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $1,175 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $960 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $960 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $960 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $960 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $960 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | PFIZER INC. | $604 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF REVACCINATING PREGNANT PARTICIPANTS DURING | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $352 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-10-29 | Novo Nordisk AS | $476 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2025 |
| 2025-10-29 | Madrigal Pharmaceuticals | $195 | Research payment | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET | 2025 |
| 2025-10-29 | Novo Nordisk AS | $125 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2025 |
| 2025-10-28 | Abbott Laboratories | $1,250 | Research payment | Cash or cash equivalent | ESPRIT Device, Vascular | NCT04227899--LIFE-BTK Randomized Controlled Trial | 2025 |
| 2025-10-27 | Janssen Research & Development, LLC | $2,371 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2025 | |
| 2025-10-25 | PFIZER INC. | $28,260 | Research payment | Cash or cash equivalent | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2025 |
| 2025-10-24 | Organon Llc | $2,500 | Research payment | Cash or cash equivalent | 8415-060 | 2025 | |
| 2025-10-24 | Abbott Laboratories | $748 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-10-24 | Takeda Pharmaceuticals U.S.A., Inc. | $585 | Research payment | Cash or cash equivalent | TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirs | 2025 | |
| 2025-10-23 | Janssen Research & Development, LLC | $3,603 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced | 2025 | |
| 2025-10-22 | Abbott Laboratories | $80 | Research payment | Cash or cash equivalent | ESPRIT Device, Vascular | NCT04227899--LIFE-BTK Randomized Controlled Trial | 2025 |
| 2025-10-20 | SANOFI US SERVICES INC. | $150 | Charitable Contribution | Cash or cash equivalent | 2025 | ||
| 2025-10-17 | Genentech, Inc. | $1,448 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | 2025 |
| 2025-10-17 | PFIZER INC. | $1,040 | Research payment | Cash or cash equivalent | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2025 |
| 2025-10-14 | BeOne Medicines USA, Inc. | $10,000 | Grant | Cash or cash equivalent | BRUKINSA Drug, Oncology | 2025 | |
| 2025-10-09 | Genentech, Inc. | $9,381 | Research payment | Cash or cash equivalent | UC P3: Double-Blind Treat Straight Through | 2025 | |
| 2025-10-09 | Humacyte Global, Inc. | $7,125 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-10-09 | Novo Nordisk AS | $162 | Research payment | Cash or cash equivalent | Drug | 4202-HEM-301 | 2025 |
The latest 200 records of 483.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Boston, MA, county Suffolk County, MA, state Massachusetts; placed by its city name.
| Measure | Place (city or town) Boston, MA | County Suffolk County, MA | State Massachusetts |
|---|---|---|---|
| Population B01003 | 666,442 | 785,121 | 7,044,056 |
| Population, 2020 census P1 | 675,647 | 797,936 | 7,029,917 |
| Median age B01002 | 33.3 | 33.9 | 40.0 |
| Under 18 B01001 | 15.1% | 16.0% | 19.4% |
| 65 and over B01001 | 13.0% | 13.3% | 17.9% |
| Households B11001 | 283,374 | 327,167 | 2,785,042 |
| Foreign born B05002 | 27.8% | 29.8% | 18.0% |
| Median household income B19013 | $97,344 | $95,631 | $103,960 |
| Median family income B19113 | $116,436 | $112,072 | $131,675 |
| Per capita income B19301 | $61,698 | $58,636 | $57,897 |
| Poverty rate B17001 | 16.6% | 16.2% | 10.0% |
| Unemployment rate B23025 | 6.1% | 6.3% | 5.2% |
| Civilian labor force B23025 | 402,354 | 468,636 | 3,911,446 |
| Mean commute (minutes) B08013 | 30.3 | 30.9 | 29.1 |
| Bachelor's degree or higher B15003 | 54.9% | 50.6% | 47.3% |
| Housing units B25001 | 310,625 | 357,290 | 3,030,406 |
| Owner-occupied B25003 | 35.7% | 36.5% | 62.5% |
| Renters B25003 | 64.3% | 63.5% | 37.5% |
| Median home value B25077 | $731,700 | $705,800 | $562,100 |
| Median gross rent B25064 | $2,147 | $2,129 | $1,762 |
| White, not Hispanic B03002 | 44.1% | 43.6% | 66.6% |
| Black B03002 | 19.3% | 17.1% | 6.4% |
| Hispanic or Latino B03002 | 19.3% | 23.2% | 13.3% |
| Asian B03002 | 10.3% | 9.2% | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Boston, MA.
Comments